Trial Outcomes & Findings for Randomized Endo-Vein Graft Prospective (NCT NCT01850082)
NCT ID: NCT01850082
Last Updated: 2021-12-15
Results Overview
Incidence of first MACE estimated via Kaplan Meier survival analysis (MACE defined as death from any cause, repeat revascularization, myocardial infarction) during the active follow-up period.
COMPLETED
NA
1150 participants
Varying timeframe for each participant with a minimum of 1 year and a maximum 4.5 Years
2021-12-15
Participant Flow
Participant milestones
| Measure |
Endoscopic Vein Harvest (EVH)
An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
Open Vein Harvest (OVH)
Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as "bridging" technique) along the course of the vein.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
|---|---|---|
|
Overall Study
STARTED
|
576
|
574
|
|
Overall Study
COMPLETED
|
576
|
574
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Randomized Endo-Vein Graft Prospective
Baseline characteristics by cohort
| Measure |
Endoscopic Vein Harvest (EVH)
n=576 Participants
An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
Open Vein Harvest (OVH)
n=574 Participants
Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as "bridging" technique) along the course of the vein.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
Total
n=1150 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
66.2 Years
STANDARD_DEVIATION 6.7 • n=5 Participants
|
66.6 Years
STANDARD_DEVIATION 7.1 • n=7 Participants
|
66.4 Years
STANDARD_DEVIATION 6.9 • n=5 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
572 Participants
n=5 Participants
|
571 Participants
n=7 Participants
|
1143 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaskan Native
|
4 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian or Pacific Islander
|
6 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Black, not of Hispanic origin
|
41 Participants
n=5 Participants
|
50 Participants
n=7 Participants
|
91 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
31 Participants
n=5 Participants
|
31 Participants
n=7 Participants
|
62 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
, not of Hispanic origin
|
490 Participants
n=5 Participants
|
484 Participants
n=7 Participants
|
974 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Other
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Missing
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Varying timeframe for each participant with a minimum of 1 year and a maximum 4.5 YearsPopulation: Events captured during the active follow-up phase of the trial (minimum of 1 year and up to 4.5 years) were included in this analysis.
Incidence of first MACE estimated via Kaplan Meier survival analysis (MACE defined as death from any cause, repeat revascularization, myocardial infarction) during the active follow-up period.
Outcome measures
| Measure |
Endoscopic Vein Harvest (EVH)
n=576 Participants
An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
Open Vein Harvest (OVH)
n=574 Participants
Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as "bridging" technique) along the course of the vein.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
|---|---|---|
|
Incidence of First MACE During Active Follow-up Period.
|
80 Participants
|
89 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: Participants with a minimum of 1 year follow-up or who died within one year.
Proportion of patients with MACE (death from any cause, repeat revascularization, myocardial infarction) at one year postoperatively.
Outcome measures
| Measure |
Endoscopic Vein Harvest (EVH)
n=571 Participants
An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
Open Vein Harvest (OVH)
n=570 Participants
Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as "bridging" technique) along the course of the vein.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
|---|---|---|
|
MACE at One Year.
|
45 Participants
|
47 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: Participants with a minimum of 3 years follow-up or died prior to 3 years.
Proportion of patients with MACE (death from any cause, repeat revascularization, myocardial infarction) at three years postoperatively.
Outcome measures
| Measure |
Endoscopic Vein Harvest (EVH)
n=568 Participants
An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
Open Vein Harvest (OVH)
n=568 Participants
Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as "bridging" technique) along the course of the vein.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
|---|---|---|
|
MACE at Three Years.
|
90 Participants
|
90 Participants
|
SECONDARY outcome
Timeframe: Varying timeframe for each participant with a minimum of 3 years and a maximum of 6.5 yearsPopulation: Events captured throughout active and passive follow-up are included in this analysis.
Incidence of first MACE estimated via Kaplan Meier survival analysis (MACE defined as death from any cause, repeat revascularization, myocardial infarction) during the entire follow-up period (active and passive).
Outcome measures
| Measure |
Endoscopic Vein Harvest (EVH)
n=576 Participants
An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
Open Vein Harvest (OVH)
n=574 Participants
Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as "bridging" technique) along the course of the vein.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
|---|---|---|
|
Incidence of First MACE Over the Entire Follow-up Period (Active and Passive).
|
126 Participants
|
135 Participants
|
Adverse Events
Endoscopic Vein Harvest (EVH)
Open Vein Harvest (OVH)
Serious adverse events
| Measure |
Endoscopic Vein Harvest (EVH)
n=576 participants at risk
An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
Open Vein Harvest (OVH)
n=574 participants at risk
Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as "bridging" technique) along the course of the vein.
Vein Harvesting Procedures: Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as "bridging" technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH.
|
|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Haemorrhagic disorder
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Heparin-induced thrombocytopenia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Immune thrombocytopenic purpura
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Splenic haematoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Acute coronary syndrome
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Acute left ventricular failure
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Angina pectoris
|
1.4%
8/576 • Number of events 8 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.4%
8/574 • Number of events 11 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Angina unstable
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.0%
6/574 • Number of events 7 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Aortic valve stenosis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Atrial fibrillation
|
4.3%
25/576 • Number of events 30 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
5.4%
31/574 • Number of events 36 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Atrial flutter
|
2.6%
15/576 • Number of events 16 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Atrial tachycardia
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Atrioventricular block
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Atrioventricular block complete
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Atrioventricular block second degree
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Bradycardia
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cardiac arrest
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cardiac failure
|
1.0%
6/576 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.6%
9/574 • Number of events 12 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cardiac failure acute
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cardiac failure congestive
|
7.1%
41/576 • Number of events 53 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
4.4%
25/574 • Number of events 50 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cardiac perforation
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cardiac tamponade
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cardiogenic shock
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cardiomyopathy
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Cor pulmonale
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Coronary artery disease
|
4.0%
23/576 • Number of events 26 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
5.2%
30/574 • Number of events 34 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Coronary artery occlusion
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.2%
7/574 • Number of events 7 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Coronary artery stenosis
|
1.4%
8/576 • Number of events 8 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.87%
5/574 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Coronary ostial stenosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Defect conduction intraventricular
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Intracardiac thrombus
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Ischaemic cardiomyopathy
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Left ventricular failure
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Myocardial infarction
|
4.7%
27/576 • Number of events 28 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
5.2%
30/574 • Number of events 34 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Nodal rhythm
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Palpitations
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Papillary muscle rupture
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Pericardial effusion
|
0.87%
5/576 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.87%
5/574 • Number of events 9 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Pericardial haemorrhage
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Pericarditis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Pericarditis uraemic
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Pulseless electrical activity
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Right ventricular failure
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Sinus arrest
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Sinus node dysfunction
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Tachycardia
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Ventricular arrhythmia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Ventricular asystole
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Ventricular fibrillation
|
0.52%
3/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.69%
4/576 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Ear and labyrinth disorders
Meniere's disease
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Endocrine disorders
Adrenocortical insufficiency acute
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Endocrine disorders
Thyroid disorder
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Eye disorders
Diplopia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Eye disorders
Endocrine ophthalmopathy
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Eye disorders
Optic ischaemic neuropathy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Eye disorders
Retinal detachment
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Abdominal wall haematoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Anal stenosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Colitis ischaemic
|
0.17%
1/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Colonic pseudo-obstruction
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Constipation
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Dieulafoy's vascular malformation
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Diverticulum
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Diverticulum intestinal haemorrhagic
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Duodenal ulcer haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Dysphagia
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Enteritis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Enterocutaneous fistula
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Epiploic appendagitis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Gastritis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Gastritis erosive
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Gastrointestinal polyp haemorrhage
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.87%
5/574 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Ileus
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Large intestinal stenosis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Large intestinal ulcer haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Enteritis infectious
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Large intestine perforation
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Mallory-Weiss syndrome
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Obstruction gastric
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Oesophageal perforation
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Oesophageal stenosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Oesophageal ulcer
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Oral disorder
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.17%
1/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Salivary gland cyst
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Varices oesophageal
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Gastrointestinal disorders
Vomiting
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Adverse drug reaction
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Asthenia
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Brain death
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Cardiac death
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Catheter site haematoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Chest discomfort
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Chest pain
|
4.0%
23/576 • Number of events 24 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
4.9%
28/574 • Number of events 34 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Complication associated with device
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Complication of device removal
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Death
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Device related thrombosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Drug withdrawal syndrome
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Impaired healing
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Ischaemic ulcer
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Non-cardiac chest pain
|
1.9%
11/576 • Number of events 12 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
2.3%
13/574 • Number of events 13 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Pacemaker generated arrhythmia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Peripheral swelling
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Pyrexia
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Submandibular mass
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Sudden cardiac death
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Systemic inflammatory response syndrome
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
General disorders
Vascular stent thrombosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Enterobacter sepsis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Hepatobiliary disorders
Bile duct obstruction
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.87%
5/576 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Hepatobiliary disorders
Drug-induced liver injury
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Hepatobiliary disorders
Gallbladder disorder
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Hepatobiliary disorders
Gallbladder perforation
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Immune system disorders
Drug hypersensitivity
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Abdominal wall abscess
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Abscess limb
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Abscess neck
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Acute sinusitis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Anal abscess
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Appendicitis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Arthritis bacterial
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Bacteraemia
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Bronchitis
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Cellulitis
|
2.1%
12/576 • Number of events 15 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.9%
11/574 • Number of events 13 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Cellulitis staphylococcal
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Colonic abscess
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Device related infection
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Diabetic foot infection
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Diverticulitis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Endocarditis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Enterococcal bacteraemia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Epididymitis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Epiglottitis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Gangrene
|
0.35%
2/576 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Gastroenteritis
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Haematoma infection
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Haemophilus infection
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Implant site infection
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Incision site cellulitis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Incision site infection
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Infected skin ulcer
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Influenza
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Localised infection
|
1.2%
7/576 • Number of events 7 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
2.6%
15/574 • Number of events 15 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Mediastinitis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Medical device site infection
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Meningitis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Osteomyelitis
|
0.87%
5/576 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 8 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Perirectal abscess
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Pneumonia
|
6.8%
39/576 • Number of events 51 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
6.3%
36/574 • Number of events 40 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Post procedural pneumonia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Postoperative wound infection
|
3.3%
19/576 • Number of events 27 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
3.1%
18/574 • Number of events 20 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Sepsis
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Septic shock
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Streptococcal infection
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Subcutaneous abscess
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Subdural empyema
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Tracheobronchitis
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Urinary tract infection
|
0.87%
5/576 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.7%
10/574 • Number of events 10 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Viral infection
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Wound abscess
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Infections and infestations
Wound infection
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Agitation postoperative
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Alcohol poisoning
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Anaemia postoperative
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Arteriovenous fistula site complication
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Arteriovenous fistula site haematoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Brachial plexus injury
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Cervical vertebral fracture
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Coronary vascular graft occlusion
|
0.87%
5/576 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Deep vein thrombosis postoperative
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Endotracheal intubation complication
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Extradural haematoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Facial bones fracture
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Fall
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Gastrointestinal injury
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Graft haemorrhage
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Haemodialysis-induced symptom
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Incision site complication
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Incision site haematoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Incision site haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Incision site pain
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Mental status changes postoperative
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Multiple fractures
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Overdose
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Perirenal haematoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Peritoneal dialysis complication
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Post procedural haematoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Post procedural haematuria
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
1.0%
6/576 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Post procedural myocardial infarction
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Post procedural swelling
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Postoperative ileus
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Postoperative respiratory distress
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Postoperative respiratory failure
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Postoperative thoracic procedure complication
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Postoperative wound complication
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Procedural complication
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Procedural hypotension
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Procedural pneumothorax
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Procedural site reaction
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Radiation dysphagia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Radiation proctitis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Scrotal haematoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Seroma
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Spinal cord injury
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Subarachnoid haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.17%
1/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Traumatic fracture
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Vascular graft occlusion
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Vascular graft stenosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Vascular pseudoaneurysm
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Vasoplegia syndrome
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Wound
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Injury, poisoning and procedural complications
Wound dehiscence
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Anticoagulation drug level above therapeutic
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Arthroscopy
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Blood potassium decreased
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Electroencephalogram
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Influenza B virus test positive
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
International normalised ratio increased
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Medical observation
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Oxygen consumption increased
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Oxygen saturation decreased
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Investigations
Transaminases increased
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.6%
9/574 • Number of events 9 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Diabetic ketoacidosis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Fluid overload
|
0.35%
2/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.87%
5/574 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Fluid retention
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Hyperglycaemic hyperosmolar nonketotic syndrome
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.0%
6/574 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Metabolism and nutrition disorders
Hypovolaemia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Cervical spinal stenosis
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Costochondritis
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Muscle haemorrhage
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
1.2%
7/576 • Number of events 9 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
2.1%
12/574 • Number of events 12 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Myopathy
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Myositis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Chemotherapy
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
1.6%
9/576 • Number of events 10 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.7%
10/574 • Number of events 10 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Musculoskeletal and connective tissue disorders
Vertebral foraminal stenosis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.17%
1/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma gastric
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon
|
0.17%
1/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour pulmonary
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear cell renal cell carcinoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon adenoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatocellular carcinoma
|
0.17%
1/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage III
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pleural effusion
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic malignant melanoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage I
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer metastatic
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.17%
1/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary tumour benign
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer metastatic
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.17%
1/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour necrosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Amyotrophic lateral sclerosis
|
0.17%
1/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Autonomic nervous system imbalance
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Basal ganglia haemorrhage
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Brain hypoxia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Carotid artery stenosis
|
1.0%
6/576 • Number of events 7 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Carotid artery thrombosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Cerebellar infarction
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Cerebral infarction
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Cerebrovascular accident
|
3.0%
17/576 • Number of events 22 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
3.5%
20/574 • Number of events 23 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Cervical myelopathy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Clonus
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Dementia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Dementia Alzheimer's type
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Dizziness
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Dizziness postural
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Dyskinesia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Embolic stroke
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Encephalopathy
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Epilepsy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Generalised tonic-clonic seizure
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Haemorrhagic cerebral infarction
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Horner's syndrome
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Intensive care unit acquired weakness
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Loss of consciousness
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Migraine
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Monoparesis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Neuralgia
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Neuroleptic malignant syndrome
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Poor quality sleep
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Presyncope
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Seizure
|
0.35%
2/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Somnolence
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Syncope
|
1.2%
7/576 • Number of events 8 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Transient ischaemic attack
|
1.0%
6/576 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Nervous system disorders
Vertebral artery thrombosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Product Issues
Device dislocation
|
0.17%
1/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Product Issues
Device failure
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Product Issues
Device kink
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Product Issues
Device malfunction
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Aggression
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Alcohol withdrawal syndrome
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Anxiety
|
0.52%
3/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Bipolar disorder
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Conversion disorder
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Delirium
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Delirium tremens
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Depression
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Drug use disorder
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Homicidal ideation
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Major depression
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Mental status changes
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Panic attack
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Stress
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Substance use disorder
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Suicidal ideation
|
0.87%
5/576 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.87%
5/574 • Number of events 11 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Suicide attempt
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Psychiatric disorders
Violence-related symptom
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Acute kidney injury
|
2.8%
16/576 • Number of events 19 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
2.3%
13/574 • Number of events 17 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Diabetic nephropathy
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
End stage renal disease
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.0%
6/574 • Number of events 7 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Nephrotic syndrome
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Cholecystectomy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Polyuria
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Renal artery stenosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Renal mass
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Renal tubular necrosis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Coronary revascularisation
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Debridement
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.87%
5/574 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial secretion retention
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Choking
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
1.7%
10/576 • Number of events 17 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
2.3%
13/574 • Number of events 18 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Diaphragmatic paralysis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Mediastinal haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
4.3%
25/576 • Number of events 27 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
3.0%
17/574 • Number of events 23 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary congestion
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
1.6%
9/576 • Number of events 10 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.6%
9/574 • Number of events 9 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory distress
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.87%
5/576 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.9%
11/574 • Number of events 11 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Respiratory, thoracic and mediastinal disorders
Thoracic haemorrhage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Skin and subcutaneous tissue disorders
Cold sweat
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Skin and subcutaneous tissue disorders
Diabetic foot
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.35%
2/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Social circumstances
Homeless
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Abdominal panniculectomy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Ankle arthroplasty
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Arteriovenous fistula operation
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Arteriovenous graft
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Bladder neoplasm surgery
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Cardiac pacemaker replacement
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Cardioversion
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Dialysis device insertion
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Drug rehabilitation
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Elective procedure
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Gastrointestinal tube insertion
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Hip arthroplasty
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.87%
5/574 • Number of events 5 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Incisional drainage
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Intervertebral disc operation
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Knee arthroplasty
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Medical device removal
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Metabolic surgery
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Multiple drug therapy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Nephrectomy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Pancreatic stent placement
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Parotidectomy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Peripheral artery bypass
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Renal transplant
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Shoulder arthroplasty
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Spinal fusion surgery
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Spinal laminectomy
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Spinal operation
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Sternal wiring
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Suture removal
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Surgical and medical procedures
Wound drainage
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Aneurysm
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Aortic aneurysm
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.0%
6/574 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Aortic dissection
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Arteriosclerosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Deep vein thrombosis
|
0.87%
5/576 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.4%
8/574 • Number of events 8 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Distributive shock
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Essential hypertension
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Haematoma
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Haemodynamic instability
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Hypertension
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Hypertensive crisis
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.35%
2/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Hypertensive emergency
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Hypotension
|
1.2%
7/576 • Number of events 7 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
1.2%
7/574 • Number of events 7 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Iliac artery occlusion
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Ischaemia
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Jugular vein thrombosis
|
0.35%
2/576 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Microembolism
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.00%
0/574 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Orthostatic hypotension
|
0.69%
4/576 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.87%
5/574 • Number of events 6 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.52%
3/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.70%
4/574 • Number of events 4 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Peripheral artery aneurysm
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Peripheral embolism
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Peripheral ischaemia
|
0.35%
2/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.52%
3/574 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.35%
2/576 • Number of events 3 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Peripheral venous disease
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Steal syndrome
|
0.17%
1/576 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 2 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Subclavian vein thrombosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Thrombophlebitis superficial
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Thrombosis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
|
Vascular disorders
Vasculitis
|
0.00%
0/576 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
0.17%
1/574 • Number of events 1 • Participant adverse event data collection stopped at the end of active follow-up. All participants had a minimum of 1 year of SAE reporting with a maximum duration of 4 years 7 months, depending on participants' time of termination from active follow-up. However, all cause mortality was collected through passive follow-up (6.5 years).
Only Serious Adverse Events were collected. Collection of SAE's occurred through routine inquiry by Site Investigator every 3 months at study visits/phone call assessments.
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place